Monthly Prescribing Reference

Imdelltra Gains Traditional Approval for Extensive Stage Small Cell Lung Cancer

Results showed tarlatamab significantly reduced the risk of death by 40% vs standard of care treatment (HR, 0.60 [95% CI, 0.47-0.77]; P .001). The Food and Drug Administration (FDA) has granted ...
Cure Today

FDA Approves Zepzelca Plus Tecentriq for Extensive-Stage Small Cell Lung Cancer

The FDA approved Zepzelca with Tecentriq for ES-SCLC, showing improved survival in the IMforte trial. The IMforte trial demonstrated a median overall survival of 13.2 months with the combination ...
Healio

Maintenance regimen a potential new standard in extensive-stage small cell lung cancer

Please provide your email address to receive an email when new articles are posted on . The addition of lurbinectedin to atezolizumab extended PFS and OS. A higher percentage of patients assigned the ...
Monthly Prescribing Reference

Lurbinectedin Plus Atezolizumab Under Review for Extensive-Stage Small-Cell Lung Cancer

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone. The Food and Drug Administration (FDA) has accepted for Priority ...
The American Journal of Managed Care

Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer

Lurbinectedin, combined with atezolizumab or atezolizumab and hyaluronidase, is FDA-approved for ES-SCLC patients without disease progression post-induction therapy. Lurbinectedin is administered ...
Seeking Alpha

FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER

Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With Extensive Stage Small Cell Lung Cancer That Has Progressed THOUSAND OAKS, Calif., Nov. 19, 2025 /PRNewswire/ -- Amgen ...
Business Wire

Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer

– 46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options – – First Phase III ...
Seeking Alpha

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway SCLC is aggressive and ...
Morningstar

FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® ...

Best time of day for cancer treatment to maximize survival, according to new study

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical study.
Cure Today

FDA Approves Imdelltra for Extensive-Stage Small Cell Lung Cancer

Imdelltra demonstrated superior overall survival and progression-free survival compared to standard chemotherapy in ES-SCLC patients post-platinum-based treatment. The DeLLphi-304 trial showed a ...